Sales 2025 by Business Segment

Sales 2025 by Geography

Historical Breakdown of Revenue by Business Segments

Net Income: Breakdown by Business Segment

Breakdown by Business Segment (EUR)
Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025

Pharmaceutical Products

       

Specialty Chemicals

89Cr 98Cr 101.89Cr 92Cr 85Cr

Total Assets

161.85Cr 173.61Cr 161.24Cr 148.95Cr 130.47Cr

Interest Expense

-10L -17L -80L -1.76Cr -34L

Income Tax Expense

12L 1.82Cr -5.3Cr -90L 7.29Cr

CAPEX

-8.86Cr -12Cr -15Cr -8.78Cr -7.85Cr

EBT

-1.46Cr 31L -24Cr -14Cr -14Cr

Gross Profit

11Cr 18Cr 16Cr 14Cr 14Cr

D&A

6.58Cr 8.91Cr 29Cr 6.81Cr 13Cr

Operating Income

-1.28Cr -8L -23Cr -12Cr -13Cr

Net Income

-1.58Cr -1.5Cr -19Cr -13Cr -21Cr

Geographical Revenue Distribution History

Geographical breakdown of sales (EUR)
Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025

Unallocated

- - 47Cr 42Cr 31Cr

Rest of Europe

- - 22Cr 21Cr 26Cr

Total Assets

- - 23Cr 24Cr 27Cr

Asia-Pacific

- - 7.93Cr 11Cr 11Cr

Total Assets

- - 8L 6L 5L

France

89Cr 98Cr 6.63Cr 7.72Cr 8.14Cr

Total Assets

161.85Cr 173.61Cr 31Cr 33Cr 25Cr

Interest Expense

-10L -17L - - -

Income Tax Expense

12L 1.82Cr - - -

D&A

6.58Cr 8.91Cr - - -

CAPEX

-8.86Cr -12Cr - - -

Gross Profit

11Cr 18Cr - - -

Net Income

-1.58Cr -1.5Cr - - -

EBT

-1.46Cr 31L - - -

Operating Income

-1.28Cr -8L - - -

North America

- - 8.63Cr 7.79Cr 7.2Cr

Total Assets

- - 2L 2L 1L

Rest of The World

- - 8.79Cr 1.22Cr 1.35Cr